AOP 03-007 - ANAHYDRET Study A single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia
Main Overview Study Protocol Appendix I Activity Sheet Contact	For further information please contact: outside Germany: AOP Orphan Pharmaceuticals AG Wilhelminenstrasse 91/II f/B4 A-1160 Vienna - AUSTRIA Phone: +43 / 1-503 72 44 Fax: +43 / 1-503 72 44-5 eMail: rudolf.widmann@aoporphan.at in Germany: Prof. Dr. med. Petro E. Petrides Hematology Oncology Center Zweibrueckenstrasse 2, am Isartor D-80331 Muenchen Phone: +49-89-229009 and +49-89-2166878-0 Fax: +49-89-229448 and +49-89-2166878-11 eMail: petrides@onkologiemuenchen.de Homepage: www.onkologiemuenchen.de Participating Countries: Austria Croatia France Germany Hungary Lituania Poland Slovenia Tchechia